XML 64 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Collaborative Research, Development and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2019
USD ($)
Feb. 28, 2018
USD ($)
Installment
Mar. 31, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized       $ 8,301,000 $ 1,254,000 $ 14,074,000 $ 1,419,000  
Intangible assets, net       7,147,000   7,147,000   $ 11,717,000
Collaboration Revenue                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized           146,000    
Serum Institute of India Pvt. Ltd. | Collaboration Revenue                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized           100,000 $ 0  
Merck, Sharp & Dohme Corp. | Sublicense Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Aggregate amount payable to acquire intangible assets   $ 21,000,000.0            
Number of installments | Installment   3            
Payment upon obligation $ 7,000,000.0 $ 7,000,000.0            
Intangible assets, net       $ 7,100,000   $ 7,100,000   $ 11,700,000
Merck, Sharp & Dohme Corp. | Sublicense Agreement | Scenario, Forecast                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Payment upon obligation     $ 7,000,000.0